Sonnet Biotherapeutics Holdings Inc (NQ: SONN )
1.560 -0.060 (-3.71%) Streaming Delayed Price Updated: 12:54 PM EST, Dec 5, 2023 Add to My Watchlist
All News about Sonnet Biotherapeutics Holdings Inc
- Annual Meeting to be Held Thursday July 15, 2021. PRINCETON, NJ / ACCESSWIRE / June 14, 2021 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a biopharmaceutical company developing innovative...
U.S. Patent and Trademark Office issued US Patent No. 11,028,166 for the Company's Fully Human Albumin Binding Domain Fusion Proteins PRINCETON, NJ / ACCESSWIRE / June 8, 2021 / Sonnet BioTherapeutics...
Topics Intellectual Property
Exposures Intellectual Property
Sonnet BioTherapeutics Provides Fiscal Year 2021 Second Quarter Business and Earnings Update
May 17, 2021
- SON-1010, fully-human IL-12 configured using FHAB platform, advancing towards IND submission - At-The-Market offering program resulted in net proceeds of $10.2 million PRINCETON, NJ / ACCESSWIRE /...
Sonnet BioTherapeutics Completes Successful GLP Repeat Dose Toxicology Study of IL12-FHAB (SON-1010) in Non-Human Primates (NHP)
May 10, 2021
- The No Observed Adverse Event Level (NOAEL) following repeated administration was more than 50 times the anticipated equivalent human clinical dose in NHP with no evidence of cytokine release...
Exposures Product Safety
- New Life Therapeutics (NLT) to develop low-dose Interleukin 6 for Diabetic Peripheral Neuropathy in ASEAN territories - Upfront and potential milestone payments totaling up to $21 Million with up to...